Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Disease diversity and FLT3 mutations.

Literature DB >> 24324154

Disease diversity and FLT3 mutations.

Catherine Choy Smith¹.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2013 PMID： 24324154 PMCID： PMC3876196 DOI： 10.1073/pnas.1320579110

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

× No keyword cloud information.

22 in total

1. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.

Authors: Scott A Armstrong; Andrew L Kung; Meghann E Mabon; Lewis B Silverman; Ronald W Stam; Monique L Den Boer; Rob Pieters; John H Kersey; Stephen E Sallan; Jonathan A Fletcher; Todd R Golub; James D Griffin; Stanley J Korsmeyer
Journal: Cancer Cell Date: 2003-02 Impact factor: 31.743

2. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors: Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal: Blood Date: 2002-06-15 Impact factor: 22.113

3. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Authors: Y Yamamoto; H Kiyoi; Y Nakano; R Suzuki; Y Kodera; S Miyawaki; N Asou; K Kuriyama; F Yagasaki; C Shimazaki; H Akiyama; K Saito; M Nishimura; T Motoji; K Shinagawa; A Takeshita; H Saito; R Ueda; R Ohno; T Naoe
Journal: Blood Date: 2001-04-15 Impact factor: 22.113

4. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors: P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal: Blood Date: 2001-09-15 Impact factor: 22.113

5. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

Authors: M Nakao; S Yokota; T Iwai; H Kaneko; S Horiike; K Kashima; Y Sonoda; T Fujimoto; S Misawa
Journal: Leukemia Date: 1996-12 Impact factor: 11.528

6. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

Authors: Neil P Shah; John M Nicoll; Bhushan Nagar; Mercedes E Gorre; Ronald L Paquette; John Kuriyan; Charles L Sawyers
Journal: Cancer Cell Date: 2002-08 Impact factor: 31.743

7. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors: Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245

8. FLT3 mutations in childhood acute lymphoblastic leukemia.

Authors: Scott A Armstrong; Meghann E Mabon; Lewis B Silverman; Aihong Li; John G Gribben; Edward A Fox; Stephen E Sallan; Stanley J Korsmeyer
Journal: Blood Date: 2003-12-11 Impact factor: 22.113

9. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.

Authors: Lei L Chen; Jonathan C Trent; Elsie F Wu; Gregory N Fuller; Latha Ramdas; Wei Zhang; Austin K Raymond; Victor G Prieto; Caroline O Oyedeji; Kelly K Hunt; Raphael E Pollock; Barry W Feig; Kimberly J Hayes; Haesun Choi; Homer A Macapinlac; Walter Hittelman; Marco A Velasco; Shreyaskumar Patel; Michael A Burgess; Robert S Benjamin; Marsha L Frazier
Journal: Cancer Res Date: 2004-09-01 Impact factor: 12.701

10. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors.

Authors: K Mackarehtschian; J D Hardin; K A Moore; S Boast; S P Goff; I R Lemischka
Journal: Immunity Date: 1995-07 Impact factor: 31.745

4 in total

1. Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach.

Authors: Xiaochu Ma; Jie Zhou; Changhao Wang; Brandon Carter-Cooper; Fan Yang; Elizabeth Larocque; Jonathan Fine; Genichiro Tsuji; Gaurav Chopra; Rena G Lapidus; Herman O Sintim
Journal: ACS Med Chem Lett Date: 2017-04-14 Impact factor: 4.345

2. SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD-mutant AML.

Authors: Suruchi Pacharne; Oliver M Dovey; Jonathan L Cooper; Muxin Gu; Mathias J Friedrich; Sandeep S Rajan; Maxim Barenboim; Grace Collord; M S Vijayabaskar; Hannes Ponstingl; Etienne De Braekeleer; Ruben Bautista; Milena Mazan; Roland Rad; Konstantinos Tzelepis; Penny Wright; Malgorzata Gozdecka; George S Vassiliou
Journal: Blood Adv Date: 2021-05-11

3. Short loop functional commonality identified in leukaemia proteome highlights crucial protein sub-networks.

Authors: Sun Sook Chung; Joseph C F Ng; Anna Laddach; N Shaun B Thomas; Franca Fraternali
Journal: NAR Genom Bioinform Date: 2021-03-01

Review 4. Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities.

Authors: Chen Hu; Jing Yang; Ziping Qi; Hong Wu; Beilei Wang; Fengming Zou; Husheng Mei; Jing Liu; Wenchao Wang; Qingsong Liu
Journal: MedComm (2020) Date: 2022-08-02

4 in total